Authors reply to Letter to the Editor- In response to: Comment on Durrani et al."s "Adalimumab for Ocular Inflammation"
Publication information:
Durrani K, Kempen J, Foster S, Group SITED (SITE) R. Authors reply to Letter to the Editor- In response to: Comment on Durrani et al."s "Adalimumab for Ocular Inflammation".
Ocul Immunol Inflamm. 2017;:1. PMID: 29043914